135 related articles for article (PubMed ID: 28085286)
1. Development of Dihydroxyphenyl Sulfonylisoindoline Derivatives as Liver-Targeting Pyruvate Dehydrogenase Kinase Inhibitors.
Tso SC; Lou M; Wu CY; Gui WJ; Chuang JL; Morlock LK; Williams NS; Wynn RM; Qi X; Chuang DT
J Med Chem; 2017 Feb; 60(3):1142-1150. PubMed ID: 28085286
[TBL] [Abstract][Full Text] [Related]
2. Structure-guided development of specific pyruvate dehydrogenase kinase inhibitors targeting the ATP-binding pocket.
Tso SC; Qi X; Gui WJ; Wu CY; Chuang JL; Wernstedt-Asterholm I; Morlock LK; Owens KR; Scherer PE; Williams NS; Tambar UK; Wynn RM; Chuang DT
J Biol Chem; 2014 Feb; 289(7):4432-43. PubMed ID: 24356970
[TBL] [Abstract][Full Text] [Related]
3. Targeting hepatic pyruvate dehydrogenase kinases restores insulin signaling and mitigates ChREBP-mediated lipogenesis in diet-induced obese mice.
Wu CY; Tso SC; Chuang JL; Gui WJ; Lou M; Sharma G; Khemtong C; Qi X; Wynn RM; Chuang DT
Mol Metab; 2018 Jun; 12():12-24. PubMed ID: 29656110
[TBL] [Abstract][Full Text] [Related]
4. A novel inhibitor of pyruvate dehydrogenase kinase stimulates myocardial carbohydrate oxidation in diet-induced obesity.
Wu CY; Satapati S; Gui W; Wynn RM; Sharma G; Lou M; Qi X; Burgess SC; Malloy C; Khemtong C; Sherry AD; Chuang DT; Merritt ME
J Biol Chem; 2018 Jun; 293(25):9604-9613. PubMed ID: 29739849
[TBL] [Abstract][Full Text] [Related]
5. Global view of cognate kinase activation by the human pyruvate dehydrogenase complex.
Guevara EL; Yang L; Birkaya B; Zhou J; Nemeria NS; Patel MS; Jordan F
Sci Rep; 2017 Feb; 7():42760. PubMed ID: 28230160
[TBL] [Abstract][Full Text] [Related]
6. Computational Study on New Natural Compound Inhibitors of Pyruvate Dehydrogenase Kinases.
Zhou X; Yu S; Su J; Sun L
Int J Mol Sci; 2016 Mar; 17(3):340. PubMed ID: 26959013
[TBL] [Abstract][Full Text] [Related]
7. Diverse mechanisms of inhibition of pyruvate dehydrogenase kinase by structurally distinct inhibitors.
Mann WR; Dragland CJ; Vinluan CC; Vedananda TR; Bell PA; Aicher TD
Biochim Biophys Acta; 2000 Jul; 1480(1-2):283-92. PubMed ID: 11004568
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic potential of the mammalian pyruvate dehydrogenase kinases in the prevention of hyperglycaemia.
Sugden MC; Holness MJ
Curr Drug Targets Immune Endocr Metabol Disord; 2002 Jul; 2(2):151-65. PubMed ID: 12476789
[TBL] [Abstract][Full Text] [Related]
9. R-lipoic acid inhibits mammalian pyruvate dehydrogenase kinase.
Korotchkina LG; Sidhu S; Patel MS
Free Radic Res; 2004 Oct; 38(10):1083-92. PubMed ID: 15512796
[TBL] [Abstract][Full Text] [Related]
10. Distinct structural mechanisms for inhibition of pyruvate dehydrogenase kinase isoforms by AZD7545, dichloroacetate, and radicicol.
Kato M; Li J; Chuang JL; Chuang DT
Structure; 2007 Aug; 15(8):992-1004. PubMed ID: 17683942
[TBL] [Abstract][Full Text] [Related]
11. VER-246608, a novel pan-isoform ATP competitive inhibitor of pyruvate dehydrogenase kinase, disrupts Warburg metabolism and induces context-dependent cytostasis in cancer cells.
Moore JD; Staniszewska A; Shaw T; D'Alessandro J; Davis B; Surgenor A; Baker L; Matassova N; Murray J; Macias A; Brough P; Wood M; Mahon PC
Oncotarget; 2014 Dec; 5(24):12862-76. PubMed ID: 25404640
[TBL] [Abstract][Full Text] [Related]
12. Pivotal role of the C-terminal DW-motif in mediating inhibition of pyruvate dehydrogenase kinase 2 by dichloroacetate.
Li J; Kato M; Chuang DT
J Biol Chem; 2009 Dec; 284(49):34458-67. PubMed ID: 19833728
[TBL] [Abstract][Full Text] [Related]
13. Investigation of potential mechanisms regulating protein expression of hepatic pyruvate dehydrogenase kinase isoforms 2 and 4 by fatty acids and thyroid hormone.
Holness MJ; Bulmer K; Smith ND; Sugden MC
Biochem J; 2003 Feb; 369(Pt 3):687-95. PubMed ID: 12435272
[TBL] [Abstract][Full Text] [Related]
14. Interaction between the individual isoenzymes of pyruvate dehydrogenase kinase and the inner lipoyl-bearing domain of transacetylase component of pyruvate dehydrogenase complex.
Tuganova A; Boulatnikov I; Popov KM
Biochem J; 2002 Aug; 366(Pt 1):129-36. PubMed ID: 11978179
[TBL] [Abstract][Full Text] [Related]
15. Pyruvate Dehydrogenase Kinases: Therapeutic Targets for Diabetes and Cancers.
Jeoung NH
Diabetes Metab J; 2015 Jun; 39(3):188-97. PubMed ID: 26124988
[TBL] [Abstract][Full Text] [Related]
16. Structural basis for the inhibition of PDK2 by novel ATP- and lipoyl-binding site targeting compounds.
Kang J; Pagire HS; Kang D; Song YH; Lee IK; Lee KT; Park CJ; Ahn JH; Kim J
Biochem Biophys Res Commun; 2020 Jun; 527(3):778-784. PubMed ID: 32444142
[TBL] [Abstract][Full Text] [Related]
17. Pyruvate dehydrogenase kinase isoform 2 activity limited and further inhibited by slowing down the rate of dissociation of ADP.
Bao H; Kasten SA; Yan X; Roche TE
Biochemistry; 2004 Oct; 43(42):13432-41. PubMed ID: 15491150
[TBL] [Abstract][Full Text] [Related]
18. Inhibitor-bound structures of human pyruvate dehydrogenase kinase 4.
Kukimoto-Niino M; Tokmakov A; Terada T; Ohbayashi N; Fujimoto T; Gomi S; Shiromizu I; Kawamoto M; Matsusue T; Shirouzu M; Yokoyama S
Acta Crystallogr D Biol Crystallogr; 2011 Sep; 67(Pt 9):763-73. PubMed ID: 21904029
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Pyruvate Dehydrogenase Kinase 2 Protects Against Hepatic Steatosis Through Modulation of Tricarboxylic Acid Cycle Anaplerosis and Ketogenesis.
Go Y; Jeong JY; Jeoung NH; Jeon JH; Park BY; Kang HJ; Ha CM; Choi YK; Lee SJ; Ham HJ; Kim BG; Park KG; Park SY; Lee CH; Choi CS; Park TS; Lee WN; Harris RA; Lee IK
Diabetes; 2016 Oct; 65(10):2876-87. PubMed ID: 27385159
[TBL] [Abstract][Full Text] [Related]
20. Identification of pyruvate dehydrogenase kinase 1 inhibitors with anti-osteosarcoma activity.
Fang A; Luo H; Liu L; Fan H; Zhou Y; Yao Y; Zhang Y
Bioorg Med Chem Lett; 2017 Dec; 27(24):5450-5453. PubMed ID: 29150396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
